abstract: BACKGROUND: @entity2736 around the elbow can result in @entity158 , @entity393 , and impaired function. We hypothesized that a single dose of radiation therapy could be administered safely and acutely after @entity130 , could decrease the number of elbows that would require surgical excision of @entity2736 , and might improve clinical results. METHODS: A prospective randomized study was conducted at three medical centers. @entity1 with an intra-articular distal humeral @entity174 or a @entity174 were enrolled. @entity1 were randomized to receive either single-fraction radiation therapy of 700 cGy immediately postoperatively (within seventy-two hours) or nothing (the control group). Clinical and radiographic assessment was performed at six weeks, three months, and six months postoperatively. All adverse events and complications were documented prospectively. RESULTS: This study was terminated prior to completion because of an unacceptably high number of adverse events reported in the treatment group. Data were available on forty-five of the forty-eight @entity1 enrolled in this study. When the rate of complications was investigated, a significant difference was detected in the frequency of nonunion between the groups. Of the nine @entity1 who had a nonunion, eight were in the treatment group. The nonunion rate was 38% (eight) of twenty-one @entity1 in the treatment group, which was significantly different from the rate of 4% (one) of twenty-four @entity1 in the control group (p = 0.007). There were no significant differences between the groups with regard to the prevalence of @entity2736 , postoperative range of motion, or Mayo Elbow Performance Score noted at the time of study termination. CONCLUSIONS: This study demonstrated that postoperative single-fraction radiation therapy, when used acutely after @entity130 for prophylaxis against @entity2736 , may play a role in increasing the rate of nonunion at the site of the @entity174 or an olecranon osteotomy. The clinical efficacy of radiation therapy could not be determined on the basis of the sample size. Further research is needed to determine the role of limited-field radiation for prophylaxis against @entity2736 after @entity130 .

title: Radiation therapy for XXXX prophylaxis acutely after @entity130 : a prospective randomized study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture-dislocation of the elbow with proximal radial and/or ulnar fractures', 'fracture']

entities_list: @entity2736 :: ('MESH:D009999', 'Disease') :: ['Heterotopic ossification', 'heterotopic ossification']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['loss of motion']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['elbow trauma']

answer: @entity2736 :: (MESH:D009999,Disease) :: ['heterotopic ossification']


abstract: A pilot study on intraoperative radiation therapy (IORT) combined with external beam radiation therapy (EBRT) in nonresectable @entity1149 ( @entity1149 ) was performed in 31 @entity1 (mean age: 66.2 years, range: 51-80; 10 anatomically and functionally, 21 functionally, nonresectable; 20 squamous-cell, 11 @entity420 ). The @entity5 was exposed by lateral thoracotomy and a staging lymph node dissection was performed (final staging 7 T1, 16 T2, 8 T3; 11 nodal positive). Ten to 20 Gy IORT (energy: 7-20 MeV electrons) were delivered to the @entity5 . Unilateral continuous positive airway pressure ventilation of the diseased lung was used to reduce the amount of healthy lung tissue in the IORT port and to minimize the ventilatory movement. Secondary collimation and direct shielding of radio-sensitive structures within the IORT port by @entity5715 sheets were used to further reduce collateral damage. Four weeks after IORT, 46 Gy EBRT (2 Gy/day 5 times a week; 8-23 MeV photons) were administered to the mediastinum and to the @entity5 -bearing area on an outpatient basis. In nodal positive cases the mediastinal dose was increased to 56 Gy. Twenty-three @entity1 were evaluable. In 13 complete, in 8 partial (50-97% regression) and in 2 minor response has been achieved. Five @entity1 experienced a recurrence (local only: 2; local and distant: 1; distant only: 2). Twelve @entity1 died of underlying @entity1576 within 6 to 25 months after IORT; 7 died of @entity5 . The overall 5-year survival rate including the incidental @entity204 is 14.7%. The recurrence-free survival rate is 53.2%.

title: Evaluating intraoperative radiation therapy (IORT) and external beam radiation therapy (EBRT) in @entity1149 ( XXXX ). Five years experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['cardio-respiratory disorders']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity5715 :: ('CHEBI:28984', 'Chemical') :: ['aluminium']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']


abstract: Preliminary studies in hematological @entity1 have indicated that treatment with rhG-CSF reduces basophil releasability ex vivo. We examined this phenomenon further, in @entity56 @entity1 . Ten @entity1 with grass pollen @entity7370 were given rhG-CSF (5 micrograms/kg/day s.c.) for 5 days, and examined before and after treatment. Basophil counts increased from 5 to 19 x 10(9)/l (P < 0.01). Total blood @entity112 increased from 80 to 160 micrograms/l (P < 0.01), corresponding to a decrease in average basophil @entity112 content from 1.5 to 0.81 pg/cell (P < 0.01). Isolated mononuclear cells showed a significantly decreased @entity112 release (HR) when stimulated with @entity3365 and grass. Whole blood experiments showed a similar decreased HR to grass and anti-IgE (P < 0.01). However, we found an increase in total blood @entity112 . We conclude that treatment with rhG-CSF (1) increases the number of circulating blood basophils, (2) reduces the average @entity112 content per basophil, and (3) reduces the basophil releasability. These findings could be due to the mobilization of immature basophils from the bone marrow.

title: Increased numbers of circulating basophils with decreased releasability after administration of rhG-CSF to XXXX @entity1 .

entities_list: @entity7370 :: ('OMIM:613207', 'Disease') :: ['rhinoconjunctivitis']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

answer: @entity56 :: (MESH:D004342,Disease) :: ['allergic']


abstract: PURPOSE: To investigate the efficacy of intravitreal injection of anti- @entity7 agents for Stage 4 @entity989 of @entity3465 . METHODS: Retrospective case series study. The medical records of @entity1 receiving intravitreal injection of anti- @entity7 agents for Stage 4 @entity989 of @entity3465 from January 2007 to May 2012 in Taipei Veterans General Hospital were reviewed. RESULTS: A total of 13 eyes of 7 @entity1 (3 @entity1 and 4 @entity1 ) with Stage 4 @entity989 of @entity3465 were included. The mean gestational age and birth weight were 27.6    2.6 weeks (range, 24.5-30.5 weeks) and 893.1    293.2 g (range, 550-1422 g), respectively. The mean age at the time of injection was 38.2    1.9 weeks (range, 36.0-41.5 weeks) postmenstrual age, and the mean follow-up period was 37.8    19.5 months (range, 11.0-67.5 months). The active neovascularization regressed rapidly, and the anatomical outcomes were favorable in all @entity1 . One eye developed recurrent @entity5861 with localized retinal detachment 21 weeks after initial treatment, which resolved after a second injection. There were no ocular or systemic complications in these @entity1 . CONCLUSION: Intravitreal injection of anti- @entity7 agents may be effective as monotherapy or as supplement to failed laser treatment for @entity1 with Stage 4 @entity989 of @entity3465 without additional surgical intervention. Further randomized controlled trials are necessary to compare the clinical efficacy and safety with other conventional interventions.

title: EFFICACY OF INTRAVITREAL INJECTION OF ANTI- XXXX AGENTS FOR STAGE 4 RETINOPATHY OF PREMATURITY.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'girls', 'boys']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['prematurity']

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor']

entities_list: @entity5861 :: ('MESH:D012166', 'Disease') :: ['retinal hemorrhage']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

answer: @entity7 :: (7422,Gene) :: ['VASCULAR ENDOTHELIAL GROWTH FACTOR']


abstract: BACKGROUND: The aim of this study was to compare the efficacy intravenous (IV) @entity3974 with @entity3652 plus @entity1363 for the prevention of shivering during spinal anesthesia (SA). MATERIALS AND METHODS: Ninety @entity1 , aged 18-65 years, undergoing lower extremity orthopedic surgery were included in the present study. SA was performed in all @entity1 with hyperbaric @entity1341 15 mg. The @entity1 were randomly allocated to receive normal saline (Group C), @entity3974 8 mg IV (Group O) or @entity3652 0.25 mg/kg IV plus @entity1363 37.5  g/kg IV (Group KM) immediately after SA. During surgery, shivering scores were recorded at 5 min intervals. The operating room temperature was maintained at 24  C. RESULTS: The incidences of shivering were 18 (60%) in Group C, 6 (20%) in Group KM and 8 (26.6%) in Group O. The difference between Groups O and Group KM with Group C was statistically significant (P < 0.05). No significant difference was noted between Groups KM with Group O in this regard (P > 0.05). Peripheral and core temperature changes throughout surgery were not significantly different among three groups (P > 0.05). Incidence (%) of @entity1833 was not significantly different between the three groups (0, 3.3, 0 in Group O, Group KM, Group C respectively, P > 0.05). CONCLUSION: Prophylactic use of @entity3974 8 mg IV was comparable to @entity3652 0.25 mg/kg IV plus @entity1363 37.5  g/kg IV in preventing shivering during SA.

title: Prophylactic use of intravenous @entity3974 versus XXXX - @entity1363 combination for prevention of shivering during spinal anesthesia: A randomized double-blind placebo-controlled trial.

entities_list: @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron']

entities_list: @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucination']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity1363 :: ('MESH:D008874', 'Chemical') :: ['midazolam']

answer: @entity3652 :: (MESH:D007649,Chemical) :: ['ketamine']


abstract: Barbiturates, such as @entity109 ( @entity13100 ), are often used during pregnancy and early neonatal life to prevent @entity302 , @entity3638 and the stressful effects of labor. However, the long-term consequences of @entity17166 exposure during the prenatal and neonatal periods have not been fully investigated. Several studies have indicated that @entity109 does affect the resulting morphology and neurochemistry of various components of the central nervous system. In the present study we have investigated the effects of 3 days of prenatal @entity109 administration (days 18-20 of gestation) on the growth and development of dendrites within the CA1 region of the hippocampus in the @entity35 . Pups were sacrificed on days 5, 10, 23, and 35 of postnatal age and the brains were processed for Golgi impregnation of neurons. The terminal and non-terminal segments of apical and basal dendrites of neurons within the CA1 region of the hippocampus were analyzed with the aid of a scanning stage on a Zeiss universal photomicroscope and a PDP 11/23 microcomputer. In general, results indicated that 3 days of prenatal @entity13100 severely suppresses the development of the dendritic tree which normally takes place during the first 35 days of postnatal life. There are significantly less branch points and the overall dendritic length of both apical and basal dendrites is reduced. These results indicate that prenatal @entity13100 , even for short periods of time, affects the normal morphological development of the hippocampus. Thus, the utilization of @entity13100 in the treatment of various @entity1 @entity74 should be questioned.

title: The influence of prenatal @entity109 exposure on the growth of dendrites in the XXXX hippocampus.

entities_list: @entity17166 :: ('MESH:C032232', 'Chemical') :: ['barbiturate']

entities_list: @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbital']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizures']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['prenatal disorders']

entities_list: @entity3638 :: ('MESH:D006932', 'Disease') :: ['hyperbilirubinemia']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: @entity712 ( @entity712 ) is an increasing burden to health care. Pharmacological treatment with @entity1289 ( @entity1289 ) inhibitors and beta blockers improve survival and reduce hospitalizations in @entity1 with low left ventricular ejection fraction (LVEF). Despite these therapies, morbidity and mortality remains problematic. Furthermore, 30% to 50% of @entity1 with @entity712 have a preserved LVEF. It is not known if treatments are of benefit in this group. DESIGN: @entity1564 in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) is a program designed to investigate the clinical usefulness of the long-acting @entity7743 blocker, @entity22666 , in a broad spectrum of @entity1 with symptomatic @entity712 . @entity1 with @entity299 , tolerant or intolerant to an @entity1289 -inhibitor, and @entity1 with preserved systolic function are included. Specifically, the CHARM program consists of 3 independent, parallel, placebo-controlled studies in @entity1 with (1) LVEF less than or equal to 40%, @entity1289 -inhibitor treated (n = 2,300); (2) LVEF less than or equal to 40%, @entity1289 -inhibitor intolerant (n = 1,700); (3) LVEF greater than 40%, not treated with @entity1289 inhibitors (n = 2,500). The 3 studies will be combined to evaluate the effect of @entity1564 cilexetil on all-cause mortality in the broad spectrum of symptomatic @entity712 . The primary objective in each trial is to evaluate the effects on the combined endpoint of cardiovascular mortality or @entity712 hospitalization. Other endpoints include the effects on @entity583 , all-cause hospitalization, and resource utilization. CHARM is intended to randomize 6,500 @entity1 with symptomatic @entity712 from 26 countries in Europe, the United States, Canada, South Africa, and Australia. The CHARM program started to enroll @entity1 in March 1999. The follow-up period is a minimum of 2 years. The study is expected to end in the third quarter of 2002.

title: @entity1564 in XXXX --assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['Chronic heart failure', 'heart failure', 'CHF']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting enzyme']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity1564 :: ('MESH:C081643', 'Chemical') :: ['Candesartan', 'candesartan']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['systolic dysfunction']

entities_list: @entity22666 :: ('MESH:C077793', 'Chemical') :: ['candesartan cilexetil']

entities_list: @entity7743 :: ('185', 'Gene') :: ['angiotensin II type 1 receptor']

answer: @entity712 :: (MESH:D006333,Disease) :: ['heart failure']


abstract: PURPOSE: The use of education is recommended to teach @entity1 self-care behaviours to reduce @entity5 , however, there is little evidence of its effectiveness or optimal timing. This educationally based @entity5 intervention trial, CAN-FIT, aimed to reduced severity of @entity1295 in radiotherapy @entity1 . METHODS: One hundred and ten @entity1 aged>= 18 years undergoing curative radiotherapy were randomly assigned to receive (1) pre- and post-radiotherapy @entity1295 education and support (RFES); (2) pre-RFES only; (3) post-RFES only; or (4) no RFES (standard care). Data collection occurred at pre- and post- radiotherapy and at 6-weeks follow-up. RESULTS: The intervention was not associated with @entity1295 at any assessment point. Significant changes were seen with secondary activity-based outcomes: Physical activity participation: Pre-RFES was associated with significantly greater increase in vigorous [Assessment (Ax)1-Ax2: 1.05 (0.24, 1.86) p<0.01: Ax2-Ax3: 1.24, (0.44, 2.03) p<0.01] and moderate physical activity participation [Ax1-Ax2: 1.4 (0.53, 2.26) p<0.01]. Post-RFES was associated with significant improvements in walking levels [Ax1-Ax3: 5.82 (0.07, 11.56) p<0.05] compared with no pre-RFES. Paid and unpaid employment: Pre-RFES was associated with slower return to pre-treatment levels of paid work [Ax2-Ax3: -0.72 (-1.41, -0.04) p<0.05] than no pre-RFES. Post-RFES was associated with decreased levels of unpaid work [Ax1-Ax3: 561.79 (51.21, 1,072.37) p<0.05] compared with no post-RFES. CONCLUSION: The CAN-FIT programme did not significantly improve the primary outcome, level of @entity1295 , regardless of when it was delivered, however, significant changes were observed in activity-based outcomes. Further investigations into educationally based programmes should target activity participation rather than changes in underlying @entity1295 to improve overall @entity1 health.

title: Is education an effective management strategy for reducing XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient']

entities_list: @entity1295 :: ('MESH:D005221', 'Disease') :: ['reduction in fatigue levels', 'fatigue']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related fatigue']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer-related fatigue']


abstract: OBJECTIVE: To assess the results of radiotherapy in the treatment of @entity263 . End points for assessment were survival, local control, development of @entity3 , and the @entity137 of therapy. MATERIALS AND METHODS: The case notes of 191 @entity1 who were treated with radical radiotherapy between 1982 and 1992 were reviewed. The pathology of 130 @entity1 was reviewed by a single pathologist. A multivariate analysis was performed to identify significant prognostic factors with regard to survival and relapse. RESULTS: One-hundred and eighty-two @entity1 were assessable. The minimum length of follow-up was one year (median = 40 months). The actuarial cause-specific 5 and 10 year survival rates were 63% and 35% respectively. Local progression occurred in 41% of @entity1 with 37% developing @entity3 . Multivariate statistical analysis demonstrated that T stage and Gleason Score were significant predictors for survival. Late complications were usually mild, with only 4% developing serious @entity1494 . CONCLUSION: Radical radiotherapy has a role in the curative treatment of @entity263 . Survival is significantly related to T stage at the time of presentation, and to the Gleason Score of the @entity5 . Survival in this series was not as good as the best surgical series, but it is still not clear which @entity1 should receive radiotherapy and which surgery as their primary management.

title: Radical radiotherapy for localized XXXX . A report of 191 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity263 :: (MESH:D011471,Disease) :: ['adenocarcinoma of the prostate']


abstract: We have previously reported that a history of pregnancy is independently associated with axillary node involvement in @entity0 @entity1 . We have now studied additional @entity1 with @entity0 and have used our data and the logistic model to produce nomograms for determining the risk of axillary node involvement, based on @entity5 size, age, and number of pregnancies. There was an increase in the incidence of axillary node involvement in @entity1 with a history of pregnancy. To exclude the confounding effect that @entity5 size or age might have on node involvement, logistic regression was performed. Pregnancy, @entity5 size, and age were the three independent variables. History of pregnancy had a significant effect on node involvement (P = 0.036) that was independent of @entity5 size and age. Nomograms were constructed from these data. Surgeons do not perform an axillary dissection in every @entity0 @entity1 . If the axilla is clinically negative and the @entity5 small, the surgeon, medical oncologist, and radiation oncologist may decide that a dissection need not be done. The nomograms in this article may allow for a more methodical choice of @entity1 for axillary dissection. Moreover, a radiation oncologist might use the nomograms to help decide whether to irradiate an undissected axilla.

title: Nomograms for determining the probability of axillary node involvement in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: Previously, a subset of T cells co-expressing the myeloid antigen @entity1116 has been described in @entity1 with @entity3052 . However, normal lymphocytes have been viewed as not expressing the @entity1116 antigen. We have developed culture conditions which allow for the rapid expansion of CD3+ @entity1116 + cells from @entity1 with @entity1778 as well as normal individuals. The protocol for cellular expansion includes the addition of interferon-gamma on day 0, @entity1192 , @entity1199 and a monoclonal antibody against CD3 on day 1 to peripheral blood lymphocytes. Using this protocol, total cell number increased more than 600-fold within 16 d of culture. Cells could be kept in culture for more than 6 months. Cells of the CD3+ @entity1116 + phenotype increased to 15.2 +/- 4.6% using this protocol after 16 d in culture. These cells have been characterized by flow cytometry and have been found to express the alpha, beta T-cell receptor, co-express the @entity3138 , @entity5893 , @entity4587 and HLA-DR antigens and did not express @entity5750 or @entity5824 antigens. Cells of the CD3+ @entity1116 + phenotype were unable to lyse @entity5 cells as determined in a 51Cr release assay. In @entity1 with @entity1860 . CD3+ @entity1116 + cells seem to be negative for expression of bcr/abl transcript in contrast to @entity1116 - cells. Our data suggest that CD3+ @entity1116 + cells do exist in peripheral blood from normal individuals.

title: Propagation of large numbers of cells of a XXXX mixed-lineage T-lymphoid/myeloid.

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukaemia']

entities_list: @entity1778 :: ('MESH:D007938', 'Disease') :: ['myeloid leukaemia']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['chronic myeloid leukaemia']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To evaluate the usefulness of endometrial aspiration cytology for assessing malignant cells of extrauterine origin. STUDY DESIGN: Endometrial cytology was performed on 224 @entity1 with primary @entity43 , 10 with @entity6887 and 45 with peritoneal @entity5 . RESULTS: Of 224 @entity1 with @entity43 , 53 (23.7%) had positive endometrial cytology. Positive rates were: stage I, 4.3%; stage II, 25.0%; stage III, 39.7%; stage IV, 34.5%. Histologic positive rates were: serous, 28.7%; mucinous, 11.4%; clear cell, 23.1%; endometrioid and unclassifiable @entity420 , 28.0%. Of 5 @entity1 with @entity43 , 2 were asymptomatic, but aspiration cytology was positive. Of 10 @entity1 with @entity6887 , 9 (90.0%) had positive endometrial cytology. The positive rate on endometrial cytology was 56.7% in @entity5 , 60.0% in @entity0 and 20.0% in @entity694 . Of 1,209 @entity1 with @entity5 , 30 (2.4%) displayed @entity43 . Of these, 7 (23.3%) had @entity13305 ; endometrial cytology was positive in 1 (14.3%). In 7 of 17 @entity1 with positive endometrial cytology, clinical diagnosis was made before @entity5 therapy. CONCLUSION: Endometrial aspiration cytology is useful for identifying nongynecologic malignant cells, diagnosing @entity43 , and determining peritoneal dissemination and @entity3 originating from @entity0 .

title: Endometrial aspiration cytology for diagnosis of peritoneal lesions in extrauterine XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian and fallopian tube cancers', 'ovarian metastasis', 'ovarian cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'gastrointestinal and breast cancers']

entities_list: @entity13305 :: ('MESH:D007725', 'Disease') :: ["Krukenberg's tumor"]

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stomach cancer', 'tumors']

entities_list: @entity6887 :: ('MESH:D005185', 'Disease') :: ['fallopian tube cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignancies']


abstract: OBJECTIVE: The objective of this study was to assess @entity1 interest in intensive meditation training for chronic symptoms. DESIGN AND SETTING: This was a cross-sectional anonymous survey among six @entity102 clinics in Baltimore including @entity740 , @entity30 , @entity10 , Renal Transplant Recipients, General Rheumatology, and @entity922 . SUBJECTS: Subjects were 1119 consecutive @entity1 registering for their appointments at these clinics. OUTCOME MEASURES: Outcome measures were 6-month @entity158 , global symptomatology, four-item perceived stress scale, use of complementary and alternative medicine (CAM) therapies, and attitudes toward use of meditation for managing symptoms. We then gave a scripted description of an intensive, 10-day meditation training retreat. @entity1 interest in attending such a retreat was assessed. RESULTS: Seventy-seven percent (77%) of @entity1 approached completed the survey. Fifty-three percent (53%) of @entity1 reported moderate to severe @entity158 over the past 6 months. Eighty percent (80%) reported use of some CAM therapy in the past. Thirty-five percent (35%) thought that learning meditation would improve their health, and 49% thought it would reduce stress. Overall, 39% reported interest in attending the intensive 10-day meditation retreat. Among those reporting moderate to severe @entity158 or stress, the percentages were higher (48% and 59%). In a univariate analysis, higher education, nonworking/disabled status, female gender, higher stress, higher @entity158 , higher symptomatology, and any CAM use were all associated with a greater odds of being moderately to very interested in an intensive 10-day meditation retreat. A multivariate model that included prior use of CAM therapies as predictors of interest in the program fit the data significantly better than a model not including CAM therapies (p = 0.0013). CONCLUSIONS: Over 50% of @entity1 followed in @entity102 clinics complain of moderate to severe @entity158 . @entity1 with persistent @entity158 or stress are more likely to be interested in intensive meditation.

title: Intensive meditation for refractory XXXX and symptoms.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['Chronic Kidney Disease']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['Headache']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's Disease"]

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['lupus clinic']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: Here, the authors describe a case of @entity7468 with @entity2527 cells of the chest cavity-which could be a distinctive form of @entity704 -which expressed @entity5893 and @entity1195 . To the authors' knowledge, there has been no previous report on this subject. A 62-year-old @entity1 presented with @entity158 in the left back associated with coughing and @entity1353 for more than 2 months prior to referral to the hospital. Palliative resection of a @entity5 was performed. During the operation, it was found that the mass occupied most of the chest invading the chest wall, aorta, vena cava, and lung tissue. The @entity1 soon died from @entity2412 in spite of anti-infection treatment. The @entity5 was composed of large areas of @entity39 and anaplastic neoplastic giant cells with high mitotic activity, and osteoclast-like cells; there was marked @entity32 . The anaplastic neoplastic giant cells were immunoreactive for CKpan, @entity5893 , @entity1195 , @entity2277 , and @entity876 . Approximately 50% to 60% of the @entity5 cells showed immunoreactivity for Ki-67. In situ hybridization for @entity9653 -encoded RNA was negative for @entity5 cells and nonneoplastic @entity2527 cells. Because this @entity5 is very rare, extensive clinical, radiological, and morphological examinations as well as immunohistochemical studies are essential to make the diagnosis.

title: XXXX with @entity2527 cells of the chest cavity: a distinctive form of @entity704 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory cell infiltration']

entities_list: @entity704 :: ('MESH:D013945', 'Disease') :: ['thymic carcinoma']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['shortness of breath']

entities_list: @entity7468 :: ('MESH:D018286', 'Disease') :: ['giant-cell anaplastic carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'mediastinal tumor']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity9653 :: ('10376', 'Species') :: ['Epstein-Barr virus']

entities_list: @entity2527 :: ('MESH:D001862', 'Disease') :: ['osteoclastic giant']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['continuous pain']

entities_list: @entity2412 :: ('MESH:D048909', 'Disease') :: ['diabetic complications']

answer: @entity7468 :: (MESH:D018286,Disease) :: ['Giant-cell anaplastic carcinoma']


abstract: BACKGROUND: Laparoscopic dismembered pyeloplasty is technically feasible for ureteropelvic junction (UPJ) obstruction although it is still challenged by its technical difficulty and time-consuming. In this study, we compared the initial results of retroperitoneal laparoscopic pyeloplasty versus a combined laparoscopic dissection and open reconstruction through a small incision in the treatment of @entity4145 . METHODS: Sixty-four @entity1 with primary @entity4145 underwent pyeloplasty: 32 @entity1 underwent laparoscopic procedure and 32 @entity1 underwent open assisted laparoscopic surgery including two steps, ie, laparoscopic dissection of the UPJ transperitoneally and then pyeloplasty via an extended small incision. The demographic data and intraoperative, postoperative and follow-up conditions of @entity1 were compared between the two groups. RESULTS: Preoperative data were comparable in the @entity1 of the two groups. The operative time was shorter (60.9 minutes vs 157.7 minutes, P < 0.0001) and the complication rate was lower (9.4% vs 31.3%, P < 0.05) in the open assisted group than in the laparoscopic group. The estimated @entity190 (42.3 ml vs 47.8 ml), time to have normal diet (37.6 hours vs 33.8 hours), and hospital stay (6.7 days vs 6.2 days) were equivalent. The operative success rate was 97% for the open assisted group and 91% for the laparoscopic group. CONCLUSIONS: The procedure of combined small incision with laparoscopy for @entity4145 is technically easy, and the results are promising. It can be used as an alternative to conventional procedures.

title: Small incision combined with laparoscopy for XXXX : comparison with retroperitoneal laparoscopic pyeloplasty.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity4145 :: ('MESH:C537373', 'Disease') :: ['UPJ obstruction']

answer: @entity4145 :: (MESH:C537373,Disease) :: ['ureteropelvic junction obstruction']


abstract: OBJECTIVE: @entity299 ( @entity299 ) is common in newborns with @entity9960 . Echocardiography before neonatal back closure has been recommended. Its utility in the era of prenatal diagnosis is unclear. STUDY DESIGN: We reviewed all newborns with @entity9960 evaluated by preoperative echocardiography at our institution over 11 years. RESULT: Seventy-six successive newborns were identified. Ninety-one percent were prenatally diagnosed with @entity9960 . In all, 1% had critical, 12% critical or non-critical and 22% critical, non-critical or possible @entity299 . The single case of critical @entity299 was both prenatally diagnosed and clinically identifiable. CONCLUSION: The prevalence of @entity299 in newborns with @entity9960 is increased compared with the general population; however, @entity66 is uncommon. We propose preoperative echocardiography is unnecessary when the @entity9960 is prenatally diagnosed, antenatal cardiac screening is complete and normal, and the newborn is clinically well.Journal of Perinatology advance online publication, 9 July 2015; doi:10.1038/jp.2015.74.

title: Is routine preoperative transthoracic echocardiography necessary in newborns with XXXX ?

entities_list: @entity9960 :: ('MESH:D008591', 'Disease') :: ['myelomeningocele']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['critical disease']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Congenital heart disease', 'CHD']

answer: @entity9960 :: (MESH:D008591,Disease) :: ['myelomeningocele']


abstract: OBJECTIVE: To examine the effect of antisperm immunity on postfertilization steps, such as implantation of embryos and fetal growth in IVF-ET treatment of @entity1 with sperm-immobilizing antibodies. DESIGN: Retrospective analysis of clinical laboratory data. SETTING: The IVF-ET program of the Department of Obstetrics and Gynecology. The University of Tokushima, School of Medicine. @entity1 : Eighteen @entity1 with sperm-immobilizing antibodies and 122 @entity249 @entity1 with nonimmune etiology as controls. Infertile couples due to a male factor and with unknown etiology were excluded. INTERVENTIONS: All @entity1 received the same IVF-ET program with GnRH agonist. MAIN OUTCOME MEASURES: Rates of fertilization and cleavage, implantation rate per embryo transferred and pregnancy rate (PR) in both test and comparison groups. RESULTS: The rate of fertilization in the antisperm group (61.3%) was significantly lower than that in the comparison group (76.8%). But the implantation rate per embryo transferred (23.5%) and consequently the modified PR per oocyte recovery procedure (34.4%) in immunologically @entity249 @entity1 were significantly higher than those in the comparison group (7.9% and 17.8%, respectively). CONCLUSIONS: Although sperm-immobilizing antibodies prevent sperm-egg interaction, they do not seem to have any adverse effects on achievement of pregnancy. Moreover, the existence of antisperm immunity in woman with antisperm antibodies is suggested to be favorable for successful pregnancy by the IVF-ET procedure.

title: High implantation rate and consequently high pregnancy rate by in vitro fertilization-embryo transfer treatment in XXXX women with antisperm antibody.

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients', 'women']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertile']

answer: @entity249 :: (MESH:D007246,Disease) :: ['infertile']


abstract: BACKGROUND: @entity298 is life-threatening without @entity1104 ( @entity1104 ) and @entity7730 ( @entity7730 ). Only a few studies in the literature addressed the relationship between age and outcomes of peritonectomy. This study was designed to review the clinical outcomes in elderly @entity1 who underwent @entity1104 and @entity7730 . METHODS: This is a retrospective study of prospectively collected data of 611 consecutive @entity1 with peritoneal @entity189 who underwent @entity1104 and @entity7730 by the same surgical team at St George Hospital in Sydney, Australia, between January 1996 and December 2013. @entity1 were divided into two groups; group 1 (<65  years old, n   =   487) and group 2 (>=  65  years old, n   =   124). Subgroup analysis was performed in @entity1 who were >= 75  years old (n   =   20). A significant difference was defined as p   <   0.05. RESULTS: There was no significant statistical difference in terms of mean total hospital stay, intensive care unit stay, high dependency unit stay and complication rates. Postoperative mortality was 2 and 3  % in groups 1 and 2, respectively. Overall survival did not reach a statistical significance between the two groups. In subgroup analysis, @entity1 showed similar morbidity results to @entity1 who were <65  years old. CONCLUSIONS: @entity1104 and @entity7730 can be safely done in the elderly. Age alone should not be the single exclusion criterion but rather taken into consideration along with other factors to determine the suitability of elderly @entity1 .

title: Cytoreductive surgery and @entity7730 for peritoneal XXXX in the elderly.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomatosis']

entities_list: @entity7730 :: ('MESH:D064146', 'Disease') :: ['PIC', 'perioperative intraperitoneal chemotherapy']

entities_list: @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['Peritoneal carcinomatosis']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinomatosis']


abstract: PURPOSE: Some @entity1 with nonmalignant @entity262 , like @entity1413 ( @entity1413 ), @entity101 , @entity6 , and @entity29 ( @entity29 ), tolerate radiation therapy poorly. Although the mechanisms of each of these disease processes are different, they share a common microvessel pathology that is potentially exacerbated by radiotherapy. This article reviews and evaluates available data examining the effects of these benign disease processes on radiation tolerance. METHODS: We conducted a thorough review of the Anglo-American medical literature from 1960 to 2001 on the effects of radiotherapy on @entity1413 , @entity101 , @entity6 , and @entity29 . RESULTS: Fifteen studies were identified that examined the effects of radiation therapy for @entity5 in @entity1 with CVDs. Thirteen of 15 studies documented greater occurrences of acute and late @entity137 (range 7%-100%). Higher rates of complications were noted especially for @entity625 CVDs. Nine studies evaluated the effects of @entity101 and @entity6 on radiation tolerance. All nine studies documented higher rates of late @entity137 than in a "control" group (range 34%-100%). When @entity1 had both @entity6 and @entity101 , the risk of late @entity137 was even higher. Six studies examined radiation tolerance of @entity1 with @entity29 irradiated to the abdomen and pelvis. Five of these six studies showed greater occurrences of acute and late @entity137 for @entity1 with @entity29 , even with precautionary measures like reduced fraction size and volume and @entity1 immobilization (13%-29%). CONCLUSION: The majority of published studies documented lower radiation tolerance for @entity1 who have @entity1413 , @entity6 , @entity101 , and @entity29 . This may reflect a publication bias, as the majority of these studies are retrospective with small numbers of @entity1 and use different scoring scales for complications. These factors may contribute to an overestimation of true radiation-induced morbidity. Although the paucity of data makes precise estimates difficult, a subset of @entity1 , in particular, those with active @entity1413 , @entity29 , or a combination of uncontrolled @entity101 with @entity1723 , is likely to be at higher risk. Future prospective trials need to document these disease entities when reporting treatment-related complications and also must monitor @entity137 associated with quiescent versus active @entity29 and @entity1413 , @entity2175 , and levels of @entity101 (controlled versus uncontrolled) matched for radiation-specific treatment sites, field size, fractionation, and total dose.

title: The effect of nonmalignant XXXX on tolerance to radiation therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['type I versus type II diabetes']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'diabetes mellitus']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['nonrheumatoid arthritis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic diseases']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['type I diabetes']

entities_list: @entity1413 :: ('MESH:D003095', 'Disease') :: ['collagen vascular disease', 'CVD']

answer: @entity262 :: (MESH:D034721,Disease) :: ['systemic disease']


abstract: UNASSIGNED: The monitoring of the minimal @entity66 by @entity3969 1 expression ( @entity4145 ( @entity8587 )) is a standardized test, which can be used in over 80% of @entity1 with @entity3052 . To investigate the prognostic value of @entity4145 ( @entity8587 ) in @entity1 undergoing allogeneic stem cell transplantation (allo- @entity12497 ) for @entity3052 , @entity4145 ( @entity8587 ) was monitored 3 months after transplantation in 139 @entity1 . @entity4145 ( @entity8587 ) positivity did not lead to any therapeutic intervention. Median follow-up was 39.3 (6.4-99.8) months. @entity1 with positive @entity4145 ( @entity8587 ) at 3 months experienced more often post-transplant relapse (27/30, 90%) than those with negative @entity4145 ( @entity8587 ) (16/109, 14.7%) (P<0.0001). Similarly, a shorter 3-year event-free survival (EFS) was observed in @entity4145 ( @entity8587 )-positive @entity1 (10% vs 72.3% in @entity4145 ( @entity8587 )-negative @entity1 , P<0.0001). The correlation between relapse and @entity4145 ( @entity8587 ) was stronger in blood than in bone marrow samples. Multivariate analysis confirmed the detrimental role of 3-month positive @entity4145 ( @entity8587 ) for relapse (hazard ratio (HR): 15.42; 95% confidence interval (CI): 7.53-31.59; P<0.0001) and EFS (HR: 10.71; 95% CI: 5.41-21.21; P<0.0001). Interestingly, 3-month chimerism was less predictive of relapse than positive @entity4145 ( @entity8587 ). In conclusion, our results demonstrate the usefulness of peripheral blood @entity4145 ( @entity8587 ) monitoring in identifying very high-risk @entity1 , who could benefit from an early preemptive treatment, and those who do not need such an intervention.Bone Marrow Transplantation advance online publication, 9 January 2017; doi:10.1038/bmt.2016.318.

title: Impact of XXXX 1 expression on outcome of @entity1 undergoing allogeneic stem cell transplantation for @entity3052 .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity3969 :: ('MESH:D009396', 'Disease') :: ["Wilms' tumor"]

answer: @entity3969 :: (MESH:D009396,Disease) :: ['Wilms' tumor']


abstract: STUDY OBJECTIVE: To test the hypothesis that sedation in elderly @entity1 is often electrophysiologically equivalent to general anesthesia (GA). DESIGN: Prospective, observational study. SETTING: Operating room of a university medical center. @entity1 : 40 elderly @entity1 (>or=65 yrs of age) undergoing @entity173 repair with spinal anesthesia and @entity1875 -based sedation. INTERVENTIONS: In the @entity1585 ( @entity1585 ; n = 15), @entity1875 sedation was administered per the usual routine of the anesthesiologist. In the @entity1585 ( @entity1585 ; n = 25), sedation was titrated to an observer's assessment of alertness/sedation (OAA/S) score of 4 (ie, lethargic in response to name called) to 5 (ie, awake and alert). MEASUREMENTS: Both @entity1 groups underwent processed electroencephalographic monitoring using bispectral index (BIS) intraoperatively. BIS levels were compared between groups to determine amount of surgical time spent in GA (BIS <or= 60). MAIN RESULTS: In the @entity1585 group, subjects spent 32.2% of surgical time at BIS levels consistent with GA. Although averaged BIS values during surgery increased from (mean +/- SD) 71 +/- 16 to 88 +/- 9 (P < 0.001), GA was still observed during 5% of surgical time in the @entity1585 group. Overall, 13 of 15 (87%) @entity1585 group @entity1 and 11 of 25 (44%) @entity1585 group @entity1 (P < 0.010) experienced some period of GA. CONCLUSIONS: BIS levels consistent with GA occur frequently in elderly @entity1 during @entity1875 -based sedation for spinal anesthesia. Altering routine practice such that sedation is titrated to a targeted clinically-determined sedation level reduces - but does not eliminate - this incidence.

title: General anesthesia occurs frequently in elderly XXXX during @entity1875 -based sedation and spinal anesthesia.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['hip fracture']

entities_list: @entity1585 :: ('MESH:D065703', 'Disease') :: ['targeted sedation group', 'routine practice group', 'RP', 'TS']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Little epidemiological information exists on @entity7184 in elite road cyclists. Anecdotal reports indicate anterior knee @entity158 and @entity615 may be common problems. PURPOSE: This study was conducted to register @entity7184 among professional road cyclists with special focus on anterior knee and @entity615 . STUDY DESIGN: Descriptive epidemiology study. METHODS: We attended training camps of 7 professional teams and interviewed 109 of 116 cyclists (94%) on @entity7184 they had experienced in the previous 12 months. Injuries that required attention from medical personnel or involved time loss from cycling were registered. Additional information on anterior knee @entity158 and @entity615 was collected using specific questionnaires. RESULTS: A total of 94 @entity130 were registered; 45% were in the lower back and 23% in the knee. Twenty-three time-loss @entity130 were registered-57% in the knee, 22% in the lower back, and 13% in the lower leg. Fifty-eight percent of all cyclists had experienced @entity615 in the previous 12 months, and 41% of all cyclists had sought medical attention for it. Thirty-six percent had experienced anterior knee @entity158 and 19% had sought medical attention for it. Few cyclists had missed competitions because of @entity158 in the lower back (6%) or anterior knee (9%). CONCLUSION: @entity615 and anterior knee @entity158 were the most prevalent @entity7184 , with @entity3331 most likely to cause @entity615 causing the highest rates of functional impairment and medical attention. CLINICAL RELEVANCE: Future efforts to prevent @entity7184 in competitive cyclists should focus on @entity615 and anterior knee @entity158 .

title: XXXX in professional road cyclists.

entities_list: @entity7184 :: ('MESH:D012090', 'Disease') :: ['overuse injuries']

entities_list: @entity3331 :: ('MESH:D007718', 'Disease') :: ['knee injuries']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['Lower back pain', 'lower back pain', 'time loss and lower back pain']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injuries']

answer: @entity7184 :: (MESH:D012090,Disease) :: ['Overuse injuries']


abstract: OBJECTIVE: To determine whether the first cycle of @entity249 ( @entity249 ) predicts treatment course and outcome. DESIGN: Retrospective study of linked cycles. SETTING: Society for Assisted Reproductive Technology Clinic Outcome Reporting System database. @entity1 (S): A total of 6,352 @entity249 @entity1 residing or treated in Massachusetts with first treatment cycle in 2004-2005 using fresh, autologous oocytes and no prior @entity249 . @entity1 were categorized by first cycle as follows: Group I, no retrieval; Group II, retrieval, no transfer; Group III, transfer, no embryo cryopreservation; Group IV, transfer plus cryopreservation; and Group V, all embryos cryopreserved. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Cumulative live-birth delivery per @entity1 , use of donor eggs, intracytoplasmic sperm injection (ICSI), or frozen embryo transfers (FET). RESULT(S): Groups differed in age, baseline FSH level, prior gravidity, diagnosis, and failure to return for Cycle 2. @entity600 per @entity1 for groups I through V for @entity1 with no delivery in Cycle I were 32.1%, 35.9%, 40.1%, 53.4%, and 51.3%, respectively. Groups I and II were more likely to subsequently use donor eggs (14.5% and 10.9%). Group II had the highest use of ICSI (73.3%); Group III had the lowest use of FET (8.9%). CONCLUSION(S): Course of treatment in the first @entity249 cycle is related to different cumulative live-birth delivery rates and eventual use of donor egg, ICSI, and FET.

title: Cycle 1 as predictor of XXXX treatment outcome over multiple cycles: an analysis of linked cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System online database.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'patients', 'Women', 'PATIENT']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['ART', 'assisted reproductive technology']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['Live-birth delivery']

answer: @entity249 :: (MESH:D007246,Disease) :: ['assisted reproductive technology']


abstract: This article provides a focused review of the literature on compulsive hoarding and presents a number of options and preliminary recommendations to be considered for DSM-V. In DSM-IV-TR, hoarding is listed as one of the diagnostic criteria for @entity3119 ( @entity3119 ). According to DSM-IV-TR, when hoarding is extreme, clinicians should consider a diagnosis of @entity3119 ( @entity3119 ) and may diagnose both @entity3119 and @entity3119 if the criteria for both are met. However, compulsive hoarding seems to frequently be independent from other neurological and @entity146 , including @entity3119 and @entity3119 . In this review, we first address whether hoarding should be considered a symptom of @entity3119 and/or a criterion of @entity3119 . Second, we address whether compulsive hoarding should be classified as a separate disorder in DSM-V, weighing the advantages and disadvantages of doing so. Finally, we discuss where compulsive hoarding should be classified in DSM-V if included as a separate disorder. We conclude that there is sufficient evidence to recommend the creation of a new disorder, provisionally called @entity74 . Given the historical link between hoarding and @entity3119 / @entity3119 , and the conservative approach adopted by DSM-V, it may make sense to provisionally list it as an obsessive-compulsive spectrum disorder. An alternative to our recommendation would be to include it in an Appendix of Criteria Sets Provided for Further Study. The creation of a new diagnosis in DSM-V would likely increase public awareness, improve identification of cases, and stimulate both research and the development of specific treatments for @entity74 .

title: XXXX : a new diagnosis for DSM-V?

entities_list: @entity3119 :: ('MESH:D009771', 'Disease') :: ['obsessive-compulsive disorder', 'OCPD', 'obsessive-compulsive personality disorder', 'OCD']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['hoarding disorder']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders']

answer: @entity74 :: (MESH:D030342,Disease) :: ['Hoarding disorder']


abstract: INTRODUCTION: @entity1 with central nervous system (CNS) @entity5 often have a long symptom interval before diagnosis. We investigated delays in diagnosis and surgical management after the first admission with @entity5 -related symptoms. MATERIAL AND METHODS: This study reviewed the medical records of 46 consecutive @entity1 with a CNS @entity5 admitted to a paediatric department. Clinical findings at the time of the first admission, duration of symptoms, time to radiological diagnosis and time to initial surgical procedures were recorded. RESULTS: The series comprised 26 supratentorial, 19 fossa posterior and one @entity5 with equal numbers of high-grade and @entity5 . @entity10 , @entity391 and lethargy were the most frequent symptoms, and pre-admission delay depended on @entity5 grade as well as location. Six cases had been diagnosed prior to admission; of the 40 undiagnosed cases, 32 (80%) were scanned within four days, but in four cases (10%) diagnosis was delayed for more than a week. Resection was performed within four days of diagnosis in 68% of @entity1 with resectable @entity5 (21/31). Initial surgical management of @entity5 causing @entity1276 was completed within four days of diagnosis in 83% (20/24). CONCLUSION: Delay in diagnosis and surgical management after the primary admission with symptoms caused by a @entity5 may influence the outcome negatively. In this review from a small centre, the majority of the cases were diagnosed and managed surgically within four days of admission and diagnosis, respectively. Criteria for good performance, i.e. accepted standards for time to diagnosis and intervention, need to be specified. FUNDING: Not relevant. TRIAL REGISTRATION: Not relevant.

title: Most central nervous system tumours in XXXX are diagnosed with little delay after admission.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['low-grade tumours', 'spinal tumour', 'tumours', 'tumour']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['Headache']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: @entity1 with advanced, incurable @entity356 may present with mild symptoms or require immediate therapeutic intervention. The influence of the intensity of preoperative symptoms on postoperative survival and quality of life (QoL) was evaluated in a palliative setting. In a historical cohort analysis of 492 @entity1 with @entity356 treated between 1992 and 2001, a total of 169 (34.4%) @entity1 had incurable disease (i.e., pTxNxM1). @entity1 were classified as having major symptoms if they presented with @entity360 (i.e., hematemesis or bloody stools), gastric inlet or outlet obstruction (i.e., symptomatic and endoscopically proven @entity850 ), or perforation caused by the @entity5 . All other @entity1 were defined as having minor symptoms. QoL was assessed prospectively using the EORTC questionnaire. The questionnaire was given to the @entity1 before operation, before discharge, and 3 months after operation; and it was analyzed by the Mann-Whitney U-test. Survival, demographic data, and histopathologic characteristics were assessed and analyzed by the log-rank test and the chi(2) test, respectively. Of the 169 @entity1 , 75 (44.3%) presented with major symptoms and 94 (55.7%) with minor symptoms. The distribution of @entity1 undergoing resection or exploration was comparable for the two groups [major: 61 (81.5%)/14 (18.5%); minor: 77 (81.9%)/17 (18.1%)]. Despite comparable demographic and histopathologic characteristics with equal hospital mortality and morbidity (14.6% vs. 8.5%/49.3% vs. 40.4%), the median survival rates in two groups were 4 and 6 months, respectively ( p < 0.05). This was not influenced by the type of operation. QoL was not different in @entity1 with major or minor symptoms before operation or 3 months thereafter. However, preoperative symptoms such as @entity1209 and melena were rated significantly higher in @entity1 with major symptoms. In @entity1 with incurable @entity356 the preoperative intensity of symptoms has a significant impact on survival and QoL, which is not influenced by the operation. The necessity of surgery in @entity1 with minor symptoms requires careful consideration.

title: Palliation of metastatic XXXX : impact of preoperative symptoms and the type of operation on survival and quality of life.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['upper gastrointestinal bleeding']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea/vomiting']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: PURPOSE: @entity1104 ( @entity1104 ) for total knee arthroplasty (TKA) has become increasingly common over the last decade. There are several reports including meta-analyses that show improved alignment, but the clinical results do not differ. Most of these studies have used a bone referencing technique to size and position the prosthesis. The question arises whether @entity1104 has a more pronounced effect on strict ligamentous referencing TKAs. METHODS: We performed a prospective cohort study comparing clinical outcome of navigated TKA (43 @entity1 ) with that of conventional TKA (122 @entity1 ). @entity1 were assessed preoperatively, and 2 and 12 months postoperatively by an independent study nurse using validated @entity1 -reported outcome tools as well as clinical examination. RESULTS: At 2 months, there was no difference between the two groups. However, after 12 months, @entity1104 was associated with significantly less @entity158 and stiffness, both at rest and during activities of daily living, as well as greater overall @entity1 satisfaction. CONCLUSION: The present study demonstrated that computer-navigated TKA significantly improves @entity1 outcome scores such as WOMAC score (P=0.002) and Knee Society score (P=0.040) 1 year after surgery in using a ligament referencing technique. Furthermore, 91% were extremely or very satisfied in the @entity1104 TKA group versus 70% after conventional TKA (P=0.007).

title: Clinical outcome using a ligament referencing technique in XXXX versus conventional technique.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1104 :: ('MESH:D000267', 'Disease') :: ['CAS', 'Computer-assisted surgery']

answer: @entity1104 :: (MESH:D000267,Disease) :: ['CAS']


abstract: BACKGROUND: GI @entity5 (GISTs), with their potential for malignant transformation, are usually treated by surgical intervention. Endoscopic treatment remains controversial. OBJECTIVE: The aim of this study was to investigate clinical outcomes associated with use of endoscopic ligation and resection for diagnosis and treatment of small EUS-suspected @entity356 . DESIGN: Prospective case series. SETTING: Academic medical center. @entity1 : Eight @entity1 with submucosal @entity356 <2 cm in diameter suspected to be GISTs. INTERVENTIONS: Endoscopic ligation and resection. MAIN OUTCOME MEASUREMENTS: Clinical/technical feasibility, success, and adverse events. RESULTS: Seven @entity1 with small EUS-suspected @entity356 were successfully treated by endoscopic ligation, with sloughing of residual tissue within 1 month. All were diagnosed pathologically with GISTs of low malignant potential. One additional @entity1 required a second ligation to remove @entity41 , also diagnosed as a GIST with low malignant potential. No perforation, massive @entity548 , or other complication requiring endoscopic or surgical intervention occurred. LIMITATIONS: Small number of @entity1 (n = 8) and limited follow-up; risk of microscopically positive margins, which limits application to lesions strongly suspected to be benign. CONCLUSIONS: Endoscopic ligation and resection shows promise as a safe and feasible technique to treat small EUS-suspected @entity356 . Controlled clinical trials with more subjects and longer follow-up are needed to confirm the value and limitations of this method.

title: Endoscopic ligation and resection for the treatment of small EUS-suspected XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stromal tumors']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric tumors', 'gastric GISTs']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric GI stromal tumors']


abstract: BACKGROUND: The increased incidence of @entity1489 after solid organ transplantation is well recognized. @entity1489 developing in transplant recipients are more aggressive in behaviour. Therapeutic options to reduce and/or delay the development of cutaneous @entity5 are therefore of interest. OBJECTIVES: The objective of this review was to summarize the available medical literature from randomized controlled trials on the use of oral @entity4878 as a preventive agent for @entity1489 in the solid organ transplant population. METHODS: Three electronic databases were searched for relevant trials: MEDLINE (1966-October 2003), EMBASE (1980-week 44, 2003) and the Cochrane Controlled Trials Register (third quarter 2003). Randomized or quasi-randomized controlled clinical trials on subjects of any age or ethnic background who had received a solid organ transplant (cardiac, renal, liver, etc.) were evaluated. All titles and abstracts found by the search strategy were independently reviewed by two researchers for inclusion into the review. RESULTS: Eighty-one abstracts were identified through the electronic databases for consideration. Review of the abstracts identified three eligible trials. One cross-over trial involving 23 subjects treated with @entity14028 25 mg daily for 12 months reported 46 @entity957 ( @entity957 ) developing in six subjects during @entity14028 treatment vs. 65 @entity957 developing in 15 subjects during the drug-free period. Another trial involving 44 subjects treated with @entity14028 30 mg daily or placebo for 6 months reported two of 19 subjects developing two @entity957 in the treatment group vs. nine of 19 subjects developing 18 new @entity1489 (15 @entity957 , one @entity1490 , two @entity1491 ) in the placebo group. One dose comparison trial involving 26 renal transplant recipients treated with @entity14028 did not find a significant difference in numbers of @entity1489 developing at the doses examined. The major limitation to the use of @entity14028 was poor tolerance due to adverse events. @entity10 , @entity1910 , @entity85 and hyperlipidaemia were the most common causes of withdrawal from treatment. No alterations in renal or liver function were detected during the periods of treatment or follow-up. CONCLUSIONS: The available data from a small number of randomized controlled trials suggest that @entity14028 may have a role in the management of solid organ transplant recipients with @entity1489 . Tolerability of the drug is a major factor limiting its use. Appropriate selection of @entity1 may help improve the risk-benefit ratio.

title: Oral XXXX for the prevention of @entity1489 in solid organ transplant recipients: a systematic review of randomized controlled trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity14028 :: ('MESH:D017255', 'Chemical') :: ['acitretin']

entities_list: @entity4878 :: ('MESH:D012176', 'Chemical') :: ['retinoids']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['Skin cancers', 'skin cancers']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas', 'SCCs']

entities_list: @entity1490 :: ('MESH:D001913', 'Disease') :: ["Bowen's disease"]

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['musculoskeletal symptoms']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['Headaches']

entities_list: @entity1491 :: ('MESH:D002280', 'Disease') :: ['basal cell carcinomas']

answer: @entity4878 :: (MESH:D012176,Chemical) :: ['retinoids']


abstract: OBJECTIVE: To evaluate clinical outcomes in a large group of @entity5 @entity1 (stage IV) following multimodal surgical therapy. SUMMARY BACKGROUND DATA: @entity1 with @entity5 have traditionally experienced poor 5-year survival (18%-30%). Few recent series have evaluated a large number of @entity1 treated with aggressive surgical rescue therapy. METHODS: This single-center retrospective review analyzes the records of 82 consecutive @entity4303 @entity1 treated by the same 2 surgeons, from August 1998 through August 2004 with a 3- to 72-month follow-up. RESULTS: Surprisingly, one third of 26 (32%) @entity1 were found to have @entity1321 ; 10 being moribund at presentation. Mesenteric encasement with @entity63 was successfully relieved in 10 of 12 cases. Five of eighty-two "terminal" @entity1 were rendered free of @entity66 . Karnofsky performance scores improved from 65 to 85 (P < 0.0001). Two- and four-year survival for @entity1 with no or unilateral liver metastases (n = 23) was 89%, while 2- and 4-year survival for @entity1 with bilateral @entity409 (n = 59) was 68% and 52% (P = 0.072), respectively. CONCLUSION: We think that all @entity1 with @entity5 should be evaluated for possible multimodal surgical therapy. @entity5 should be resected, even in the presence of distant metastases to prevent future @entity1321 . The "wait and see" method of management of this slow-growing @entity5 no longer has merit. We offer an algorithm for the surgical evaluation and management of these @entity1 .

title: Surgical treatment of XXXX : lessons learned.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['macroscopic disease']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['intestinal ischemia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Primary tumors', 'advanced-stage carcinoid']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity1321 :: ('MESH:D007415', 'Disease') :: ['intestinal obstruction', 'intestinal obstructions']

entities_list: @entity4303 :: ('MESH:D002276', 'Disease') :: ['carcinoid']

answer: @entity5 :: (MESH:D009369,Disease) :: ['advanced-stage carcinoid tumors']


abstract: BACKGROUND: Prior studies documented poorer outcomes in @entity1 with @entity135 ( @entity135 ) relative to those with @entity320 at other sites. We evaluated survival differences attributable to @entity5 location in @entity1 with @entity135 . METHODS: We queried the Surveillance, Epidemiology, and End Results (SEER) database for @entity1 undergoing surgery for @entity135 from 1988 to 2006, excluding @entity1 without biopsy-proven diagnoses, those diagnosed at autopsy, and @entity1 with distant metastases. Using the Kaplan-Meier method, we assessed @entity1 , @entity5 , and treatment-specific factors on @entity1349 ( @entity1349 ) and @entity320 ( @entity320 ). Cox proportional hazards models assessed the role of @entity5 location (ear, eyelid, face, lip, scalp/neck) on @entity1349 and @entity320 , while controlling for @entity1 age, gender, race, @entity5 thickness, @entity5 ulceration, lymph node status, histologic subtype, type of surgery, and use of radiation. Risks of overall and @entity320 -specific mortality were reported as hazard ratios (HR) with 95% confidence intervals (CI). RESULTS: Among 27,097 @entity1 , 10-y rates of @entity1349 and @entity320 were 56.1% and 84.7%, respectively. On multivariate analysis, scalp/neck primary site was associated with an increased risk of overall (HR 1.20, CI 1.14-1.26; P < 0.001) and @entity320 -specific mortality (HR 1.64, CI 1.49-1.80, P < 0.001) relative to @entity320 of the face. @entity5 of the lip had poorer @entity320 (HR 1.55; CI 1.05-2.28, P = 0.03) but not @entity1349 (HR 1.03, CI 0.80-1.34; P = 0.80). CONCLUSIONS: @entity1 with @entity320 of the scalp/neck have poorer @entity1349 and @entity320 and those with lip @entity320 have poorer @entity320 . These anatomic areas should not be overlooked when performing skin examinations.

title: @entity5 location predicts survival in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['CHNM', 'cutaneous head and neck melanoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanomas', 'melanoma specific survival', 'MSS']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity135 :: (MESH:D006258,Disease) :: ['cutaneous head and neck melanoma']


abstract: BACKGROUNDS/AIMS: @entity9296 ( @entity9296 ) and @entity7157 (BCCA) are @entity99 . Prior reports concerning the proper surgical treatment and long-term survival are scarce. We report our experience and survival outcome of 30 @entity1 over the last 25 years. METHODS: We retrospectively reviewed the clinicopathologic data of the pathologically confirmed 18 @entity9296 and 12 BCCA @entity1 , who underwent operations from 1983 to 2006, at the Seoul National University Hospital. RESULTS: The @entity1 consisted of 8 @entity1 and 22 @entity1 with a mean age of 51 years. With abdominal computed tomography scans, 73.3% (n=22) were preoperatively diagnosed as @entity9296 or BCCA, and differentiating BCCA from @entity9296 was accurate in 58.3% @entity1 . R0 resection was achieved in 90% (n=27). The differentiating factors included the presence of mural nodule (4/18 vs. 8/12; p=0.009) and mucinous content (2/9 vs. 8/1; p=0.005), and @entity5 size tending to be larger in BCCA (11.7 cm vs. 7.9 cm; p=0.067). Overall 5-year and 10-year survival rates of BCCA were 72.9% and 60.9%, respectively. Of @entity1 with BCCA, 4 experienced recurrence. In case of recurrence, @entity1 tended to be younger than 50 years (p=0.061) and the lesions tended to be larger than those without recurrence (p=0.088). CONCLUSIONS: Preoperative differentiations of @entity9296 from simple cyst, and BCCA from @entity9296 are still difficult. Complete @entity5 , via major hepatectomy, should be considered, especially in the younger age group with large @entity5 .

title: Clinical outcome and long term results after surgical treatment of @entity9296 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'removal of the tumor']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['rare cystic hepatic neoplasms']

entities_list: @entity9296 :: ('MESH:D003537', 'Disease') :: ['Biliary cystadenoma', 'BCA']

entities_list: @entity7157 :: ('MESH:D003536', 'Disease') :: ['cystadenocarcinoma']

answer: @entity7157 :: (MESH:D003536,Disease) :: ['cystadenocarcinoma']


abstract: Total hip arthroplasty ( @entity2445 ) and total knee arthroplasty (PTG) are surgical interventions aiming at functional improvement. They therefore cannot accommodate any " @entity16 " produced, notably by @entity1031 ( @entity1031 ). Use of the necessary thromboprophylaxis has made STEs rare (<3% after @entity2445 and 2% after TKA). @entity1151 ( @entity1151 ) is exceptional (0.3%) and only accounts for 15% of the deaths occurring in the 1st postoperative month. However, @entity66 is significantly associated with @entity1211 . The causes of STEs are mechanical, directly related to surgical maneuvers, but also biological (familial or acquired @entity49 , @entity49 , particularly associated with hip surgery). Delayed resumption of walking, which promotes @entity2979 , has been improved by modern pain management techniques. There is consensus on the need to prolong thromboprophylaxis after @entity2445 , but it is more controversial after TKA and depends on the added risk factors. In France, prolonged prevention is widespread. The relatively low @entity1031 rate should be put into perspective with the risk of @entity548 . The surgeon should be particularly attentive to the risk of @entity548 at the operative site because it generates a risk of @entity295 , and a risk of stiffness for TKA. The risk of @entity548 essentially results from the misuse of all the anticoagulants, particularly observed with the anti- @entity2067 medications because their use is more restricted. The risk of @entity548 has become quite comparable to the risk of @entity1031 with prophylaxis. To prevent this event, the prescriber must know the characteristics of each drug : Tmax, half-life, mode of elimination, as well as the risk of accumulation in the @entity1 receiving such treatment ( @entity1011 clearance). Currently, the thrombohemorrhagic risk for each @entity1 must be assessed. Per os treatment with @entity14534 is highly advantageous because it is easy to use, there is no @entity882 induced by heparin, and there is no need for complementary monitoring exams, thus reducing costs. Efficacy in terms of prevention and hemorrhagic risk, demonstrated in phase II studies, must be confirmed by widespread used in real-life conditions.

title: [Antithrombotic prophylaxis after XXXX and TKA: the surgeon's point of view].

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['atherothrombotic disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'bleeding']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombopenia']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['collateral damage']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['thrombophilia', 'hypercoagulability']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['Pulmonary embolism', 'PE']

entities_list: @entity14534 :: ('MESH:C453962', 'Chemical') :: ['Dabigatran etexilate']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism', 'STE', 'symptomatic thromboembolic events']

entities_list: @entity2979 :: ('MESH:D054070', 'Disease') :: ['venous stasis']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['thromboembolic venous disease']

answer: @entity2445 :: (MESH:D013619,Chemical) :: ['THA']


abstract: Vertebrate species display consistent left-right asymmetry in the arrangement of their internal organs. This asymmetry reflects the establishment of the left-right axis and the alignment of the organs along this axis during development. Members of the @entity11340 family of molecules have been implicated in both the establishment and signaling of left-right axis information. Asymmetric expression of one member, nodal (called @entity11341 in the frog, @entity1238 ), is highly conserved among species. The nodal-related genes are normally expressed in the left lateral plate mesoderm prior to the development of morphologic asymmetry. Expression patterns of nodal have been correlated with heart situs in @entity19 , @entity1573 , and frog and our previous work has implicated the dorsal midline structures in the regulation of nodal expression and cardiac laterality. In this study, three approaches were used to address the embryologic and molecular basis of asymmetric @entity11341 expression. First, notochord and lateral plate recombinants were performed and showed that notochord can repress @entity11341 expression in lateral plate mesoderm explants derived from either the left or the right side. Second, lateral plate mesoderm grafts indicated that @entity11341 expression is specified but not determined at neurula stages and can subsequently be repatterned. These experiments suggest that a repressive signal from the notochord is required for maintenance of asymmetric @entity11341 expression and that @entity11341 expression is regulated by signals outside of the lateral plate mesoderm. Third, candidate molecules were injected to test for their ability to alter @entity11341 expression pattern in the lateral plate. Late injection of activin protein on the right side of the embryo induced ectopic @entity11341 expression and randomized cardiac orientation. This suggests that activin or a related @entity11340 molecule is involved in the proximal regulation of asymmetric @entity11341 expression.

title: Maintenance of asymmetric nodal expression in XXXX .

entities_list: @entity1238 :: ('8355', 'Species') :: ['Xenopus laevis']

answer: @entity1238 :: (8355,Species) :: ['Xenopus laevis']


abstract: PURPOSE: We investigated the synergistic effect of hyperbaric @entity26 (HBO) and @entity7420 ( @entity7420 ) on adhesion formation in @entity35 . METHODS: 40 adult male @entity35 (250-350 g) were divided into 4 groups. In group-1, no further management was undertaken. Group-2 received HBO therapy, group-3 was treated with 50 ug/kg subcutaneous @entity7420 once daily for 7 days following laparatomy and cecal abrasion and group-4 was given both @entity7420 and HBO therapies. On the 7th day, all @entity35 were sacrificed and adhesions were scored. Tissue samples from adhesions and peritonea and cecum wall were examined both pathologically and biochemically for tissue @entity720 content. RESULTS: No mortality occurred in study groups. When the groups were evaluated according to the adhesion numbers and grades, there was a statistically significant difference between the control and groups 3 and 4 (P < 0.001). There was no statistically significant difference between groups 1 and 2 (p > 0.05). HBO + @entity7420 group was significantly different from control, HBO and @entity7420 groups, regarding @entity720 contents (p = 0.005). @entity32 and @entity82 did not differ significantly among the groups (p = 0.248), (p = 0.213). CONCLUSION: HBO treatment could not reduce the adhesion formation alone. Combined use of HBO and @entity7420 , has a markedly preventive effect on @entity86 formation (Tab. 1, Fig. 2, Ref. 57).

title: Synergistic effects of hyperbaric @entity26 and granulocytecolony stimulating factor on @entity86 formation in a XXXX cecal abrasion model.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammation']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity7420 :: ('25610(Tax:10116)', 'Gene') :: ['granulocyte-colony stimulating factor', 'G-CSF']

entities_list: @entity720 :: ('CHEBI:18095', 'Chemical') :: ['hydroxyproline']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative adhesion']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The screen-film system is replaced by computed radiography system for recording the images of the @entity1 during X-ray radiography examinations. The change in imaging system requires the re-establishment of the institutional diagnostic reference levels (DRLs) for different types of X-ray examinations conducted at the hospital. For this purpose, @entity1 specific parameters [age, height, weight, body mass index (BMI), @entity2996 ( @entity2996 )] and machine specific parameters (kVp, mAs, distance and field sizes) of 1875 @entity1 during 21 different types of X-ray examinations were recorded for estimating the entrance skin dose (ESD). The ESD for each of these @entity1 were estimated using measured X-ray beam output and the standard value of the back scatter factor. Five number summary was calculated for all the data for their presentation in the Box-Whisker plot, which provides the statistical distribution of the data. The data collected indicates that majorly performed examinations are cervical spine AP, Chest PA and Knee @entity6070 with percentage contributions of 16.05, 16 and 8.27% respectively. The lowest contribution comes from Hip @entity6070 which is about 1.01%. The ratio of measured ESD (maximum to minimum) for these examinations is found to be highest for the cervical spine AP with a value of 50 followed by Thoracic spine AP of 32.36. The ESD ratio for Chest PA, Knee @entity6070 and Lumbar Spine AP are 30.75, 30.4 and 30.2 respectively. The lowest ESD ratio is for Hip @entity6070 which is 2.68. The third quartile values of ESDs are established as the institutional DRLs. The ESD values obtained for 21 different X-ray projections are either comparable or lesser than the reported national/international values.

title: Radiation dose to XXXX from X-ray radiographic examinations using computed radiography imaging system.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2996 :: ('MESH:C564543', 'Disease') :: ['OID', 'object to image distance']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The correlation between elevated level of a new plasma @entity5 marker, Lipid Associated @entity3167 (LASA) and detection of bone marrow heterotopic epithelial cells by monoclonal antibodies using an immunocytologic technique, associated with the study of the proliferative activity of these heterotopic cells by measurement of their @entity894 ( @entity894 ) was analyzed in 158 samples obtained from 94 @entity0 @entity1 . Six different groups of @entity1 in complete remission of @entity0 , after radical treatment of the primary (minimal @entity66 ( @entity4145 ] were defined, according to the presence with or without proliferative activity of heterotopic cells in the bone marrow or the absence of such cells and to the level, normal or elevated of LASA in the serum of the same @entity1 at the same time. 115 samples (73%) of the @entity1 had an elevated LASA level at the time of the study among which 71 (45%) came from @entity1 in which heterotopic cells were detected in the bone marrow, 32 (20%) of which with proliferative activity ( @entity894 +) 39 (25%) without ( @entity894 -). In 44 (28%) samples, no heterotopic cells were detected in the B.M. 43 samples (27%) of the @entity1 had a normal LASA level. In 29 (18%) no heterotopic cells could be detected in the B.M. In only 14 could such cells be found, 5 with @entity894 +, 9 with @entity894 -. Both of these cytological and biological parameters can be useful markers of minimal @entity66 and help to determine the prognosis and define optimal therapeutic strategy for curable @entity0 . Their prognostic value in predicting relapse awaits further observation with longer follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Relationship between proliferative activity of bone marrow micrometastasis and plasmatic level of a new @entity5 marker: lipid associated @entity3167 (LASA) in XXXX @entity0 .

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['Sialic Acid']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity894 :: ('MESH:C566784', 'Disease') :: ['labelling index', 'LI']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: AIMS: Hypofractionated accelerated radiotherapy with concurrent @entity3003 utilises both advantages of altered fractionation and synchronous chemotherapy to maximise local control in locally advanced @entity135 . Such fractionation schedules are increasingly used in the intensity-modulated radiotherapy era and the aim of this study was to determine the outcome of hypofractionated accelerated radiotherapy with @entity3003 . MATERIALS AND METHODS: One hundred and fifty consecutive @entity1 with @entity957 of the larynx, oropharynx, oral cavity and hypopharynx (International Union Against Cancer [IUAC] stage II-IV) treated with 55Gy in 20 fractions over 25 days with concurrent @entity3003 were analysed. Outcome measures were 2 year overall survival, local control and disease-free survival. RESULTS: The median follow-up in surviving @entity1 was 25 months. IUAC stages: II n=15; III n=42; IV n=93. Two year overall survival for all @entity1 was 74.9% (95% confidence interval 66.0-81.7%). Two year local control was 78.3% (95% confidence interval 69.6-84.8%). Two year disease-free survival was 67.2% (95% confidence interval 58.3-74.7%). There were 135 @entity1 with @entity5 . For these @entity1 , the 2 year overall survival, local control and disease-free survival were 74.3% (95% confidence interval 64.7-81.6%), 79.1% (95% confidence interval 69.8-85.9%) and 67.6% (95% confidence interval 58.0-75.4%), respectively. Prolonged grade 3 and 4 @entity33 seen at >= 4 weeks were present in 9 and 0.7%, respectively. Late feeding dysfunction (determined by dependence on a feeding tube at 1 year) was seen in 13% of the surviving @entity1 at 1 year. CONCLUSION: Hypofractionated accelerated radiotherapy with concurrent @entity3003 achieves a high local control. This regimen should be considered for a radiotherapy dose-escalation study using intensity-modulated radiotherapy.

title: Hypofractionated accelerated radiotherapy with concurrent XXXX for locally advanced @entity957 of the @entity135 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III and IV disease']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']


abstract: Amoeboid microglial subpopulations visualized by antibodies against ionized @entity460 -binding adapter molecule 1, @entity469 , and @entity1195 enter the forebrain starting at 4.5 postovulatory or gestational weeks (gw). They penetrate the telencephalon and diencephalon via the meninges, choroid plexus, and ventricular zone. Early colonization by amoeboid microglia-macrophages is first restricted to the white matter, where these cells migrate and accumulate in patches at the junctions of white-matter pathways, such as the three junctions that the internal capsule makes with the thalamocortical projection, external capsule and cerebral peduncle, respectively. In the cerebral cortex anlage, migration is mainly radial and tangential towards the immature white matter, subplate layer, and cortical plate, whereas pial cells populate the prospective layer I. A second wave of microglial cells penetrates the brain via the vascular route at about 12-13 gw and remains confined to the white matter. Two main findings deserve emphasis. First, microglia accumulate at 10-12 gw at the cortical plate-subplate junction, where the first synapses are detected. Second, microglia accumulate in restricted laminar bands, most notably around 19-30 gw, at the axonal crossroads in the white matter (semiovale centre) rostrally, extending caudally in the immature white matter to the visual radiations. This accumulation of proliferating microglia is located at the site of white-matter injury in premature neonates. The spatiotemporal organization of microglia in the immature white and grey matter suggests that these cells may play active roles in developmental processes such as axonal guidance, synaptogenesis, and @entity245 as well as in injuries to the developing brain, in particular in the periventricular white-matter injury of preterm @entity1 .

title: Early microglial colonization of the @entity1 forebrain and possible involvement in periventricular white-matter injury of preterm XXXX .

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['neurodevelopmental apoptosis']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity1 :: (9606,Species) :: ['infants']


abstract: While @entity1024 antagonists have been shown to attenuate @entity528 in focal @entity2806 , few studies have examined whether continuous or multiple dose treatment is necessary for maximum efficacy. We studied the effect of a loading dose only or load plus maintenance infusion using several non-competitive @entity1024 antagonists ( @entity14031 , @entity3982 , @entity3390 ) and the levorotatory enantiomer of @entity14031 ( @entity14031 ) in a @entity95 model of focal @entity2806 . Forty-seven anesthetized @entity95 underwent occlusion of the left internal carotid, anterior cerebral and middle cerebral arteries for 2 h followed by 4 h of reperfusion. Drugs were administered 10 min after occlusion. @entity14031 and @entity3982 protected against @entity4 only when given as load plus maintenance (29% and 31% reduction, respectively), while both load only and load plus maintenance of @entity3390 protected against @entity4 (26% and 31% reduction, respectively). @entity14031 load plus maintenance also protected against @entity4 (25% reduction). However, @entity14031 and @entity3982 both required maintenance infusion to protect against @entity528 (24% and 27% reduction in area of @entity528 , respectively), while @entity14031 failed to protect against @entity528 even when given as load plus maintenance. Administration of @entity3390 as load plus maintenance reduced @entity528 by 23%, but this difference was not quite statistically significant. These results suggest that processes of @entity2806 , such as @entity130 , continue for several hours beyond the initial period of focal @entity63 , and that non-competitive @entity1024 antagonists require more prolonged administration to achieve neuroprotection.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Neuroprotection by @entity1024 antagonists in focal XXXX is dependent on continued maintenance dosing.

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia', 'ischemic damage']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edema', 'ischemic edema']

entities_list: @entity14031 :: ('MESH:D003915', 'Chemical') :: ['Levomethorphan', 'levomethorphan', 'Dextromethorphan', 'dextromethorphan']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity3982 :: ('MESH:D003917', 'Chemical') :: ['dextrorphan']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['ischemic neuronal damage', 'neuronal injury', 'neuronal damage']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['excitotoxic injury']

answer: @entity2806 :: (MESH:D002545,Disease) :: ['cerebral ischemia']


abstract: BACKGROUND: The fact that prognoses remain poor in @entity1 with advanced @entity157 highlights the demand for suitable animal models to facilitate the development of anti- @entity5 medications. This study employed a relatively non-invasive approach to establish an @entity157 model in immune-competent @entity35 . This was done by ultrasound-guided implantation of @entity5 cells and the model was used to evaluate the therapeutic efficacy of short-term and low-dose @entity1259 chemotherapy. METHODS: @entity35 @entity7283 cells were injected percutaneously into the liver lobes of @entity35 under the guidance of high resolution ultrasound. The implantation rate and the correlation between dissected and ultrasound-measured @entity5 sizes were evaluated. A similar induction procedure was performed by means of laparotomy in a different group of @entity35 . Pairs of @entity5 measurement were compared by ultrasound and computerized tomography scan. @entity35 with a successful establishment of the @entity5 were divided into the treatment (7-day low-dose @entity1259 ) group and the control group. The @entity5 sizes were non-invasively monitored by the same ultrasound machine. Blood and @entity5 tissues from @entity5 -bearing @entity35 were examined by biochemical and histological analysis respectively. RESULTS: Ultrasound-guided implantation of @entity7283 cells led to the formation of @entity157 in 60.4% (55/91) of the @entity35 . Moreover, @entity5 sizes measured by ultrasound significantly correlated with those measured by calipers after sacrificing the animals (P < 0.00001). The rate of @entity5 induction by ultrasound-guided implantation was comparable to that of laparotomy (55/91, 60.4% vs. 39/52, 75%) and no significant difference in sizes of @entity5 was noted between the two groups. There was a significant correlation in @entity5 size measurement by ultrasound and computerized tomography scan. In @entity5 -bearing @entity35 , short-term and low-dose @entity1259 chemotherapy caused a significant reduction in @entity5 growth, and was found to be associated with enhanced apoptosis and attenuated proliferation as well as a decrease in the microvessel density in @entity5 . CONCLUSIONS: Ultrasound-guided implantation of @entity7283 cells is an effective means of @entity157 in @entity35 . Short-term and low-dose @entity1259 chemotherapy had perturbed @entity5 progression by inducing apoptosis and neovascularization blockade.

title: Rapid induction of @entity157 in immune-competent XXXX by non-invasive ultrasound-guided cells implantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity7283 :: ('MESH:D008114', 'Disease') :: ['Novikoff hepatoma']

entities_list: @entity35 :: ('10116', 'Species') :: ['Rat', 'Sprague-Dawley rats', 'Rats', 'rats']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['orthotopic hepatocellular carcinoma', 'hepatocellular carcinoma', 'establishing orthotopic hepatocellular carcinoma']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: OBJECTIVE: To report a case of @entity3126 associated with the use of ocular @entity20542 , a nonselective beta-blocker. CASE SUMMARY: A 72-year-old @entity1 with no history of @entity299 presented to the emergency room with signs and symptoms consistent with @entity3126 . The @entity1 had used @entity20542 eyedrops approximately 1 hour before becoming symptomatic. When rechallenged inadvertently while hospitalized, the @entity1 again became symptomatic. The @entity1 's @entity20542 eyedrops then were substituted with @entity9004 eyedrops. She continued to be free of symptoms of @entity3126 at subsequent clinic visits 1, 4, and 6 weeks following discharge. DISCUSSION: This is the first reported case of @entity3126 associated with @entity20542 . There was a reasonable temporal association between use of the eyedrops and the onset of symptoms. Beta-blockers may cause @entity3126 secondary to their negative inotropic and negative chronotropic effects. The drug's lipid solubility or a deficiency in the enzyme responsible for its metabolism may have allowed the drug to accumulate to a critical concentration over the 6-week period of use. CONCLUSIONS: Ocular beta-blockers must be used with caution in @entity1 with relative contraindications to beta-blockade. This case illustrates that these agents must be used prudently even in @entity1 with no history of symptomatic @entity712 .

title: XXXX associated with ocular @entity20542 use.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema', 'cardiogenic pulmonary edema']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['pulmonary or cardiac disease']

entities_list: @entity20542 :: ('MESH:D014290', 'Chemical') :: ['metipranolol']

entities_list: @entity9004 :: ('MESH:D015784', 'Chemical') :: ['betaxolol']

answer: @entity3126 :: (MESH:D011654,Disease) :: ['Acute pulmonary edema']